Skip to content

DiAoXinXueKang capsule for primary hyperuricemia: a randomized controlled trial

DiAoXinXueKang capsule for primary hyperuricemia: a randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17014035
Enrollment
Unknown
Registered
2017-12-19
Start date
2017-12-27
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hyperuricemia

Interventions

experimental group:DiAoXinXueKang capsule+ usual care
control group:usual care

Sponsors

Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Male, Aged 18-60 years old; (2) Consistent with the diagnosis of hyperuricemia; (3) Drugs that affect blood uric acid metabolism have not been taken recently, including benzothiofuran derivatives (benzbromarone, benzodine), probenecid, colchicine, salicylate (aspirin), selective and nonselective Non-steroidal anti-inflammatory drugs, thiazides, furosemide diuretics, cyclosporine, pyrazinamide, losartan, and other patients who have used other uric acid lowering measures; or discontinued for more than 2 weeks; (4) Cooperate with various research examinations and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Secondary hyperuricemia; (2) Clinical manifestations of gout or gout, including acute gouty arthritis, tophi and chronic arthritis, severe deformity, incapacity, and kidney disease; (3) severe heart, lung, brain, liver, kidney and hematopoietic system comorbidities, including hypertension, hepatitis B or C, kidney stones, polycystic kidney disease, hematological malignancies or other unidentified malignant Disease and HIV; (4) Patients with history of organ transplant or history of cardiopulmonary bypass surgery; (5) Patients who participated in other drug clinical trials within three months; (6) Unwilling to cooperate and mental patients; (7) Allergic constitution and allergy to a variety of drugs.

Design outcomes

Primary

MeasureTime frame
blood uric acid;

Secondary

MeasureTime frame
serum creatinine;urine uric acid;24 hour uric acid excretion index;urine creatinine;

Countries

China

Contacts

Public ContactTao Wang

Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine

wangtao@tjutcm.edu.cn+86 022-27386453

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026